Cargando…

Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study

BACKGROUND: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion. This study is designed to examine cancer incidence associated with use of insulin glargine vs. intermediate/long-acting human insulin (HI). METHODOLOG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chia-Hsuin, Toh, Sengwee, Lin, Jou-Wei, Chen, Shu-Ting, Kuo, Chuei-Wen, Chuang, Lee-Ming, Lai, Mei-Shu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124499/ https://www.ncbi.nlm.nih.gov/pubmed/21738645 http://dx.doi.org/10.1371/journal.pone.0021368

Ejemplares similares

Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study
por: Chang, Chia-Hsuin, et al.
Publicado: (2016)

Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study
por: Chang, Chia-Hsuin, et al.
Publicado: (2014)

Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence
por: Shau, Wen-Yi, et al.
Publicado: (2012)

Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study
por: Lee, Yen-Chieh, et al.
Publicado: (2014)

Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States
por: Rai, Ashish, et al.
Publicado: (2023)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

Stent revascularization versus bypass surgery for peripheral artery disease in type 2 diabetic patients – an instrumental variable analysis
por: Chang, Chia-Hsuin, et al.
Publicado: (2016)

The association between new onset atrial fibrillation and incident cancer—A nationwide cohort study
por: Hung, Chi-Sheng, et al.
Publicado: (2018)

Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case–Crossover Study
por: Wu, Cho-Kai, et al.
Publicado: (2019)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Nationwide epidemiological study of severe gallstone disease in Taiwan
por: Huang, John, et al.
Publicado: (2009)

Microalbuminuria and diabetic retinopathy in type 2 diabetic patients: From risk association to risk prediction
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Fetal exposure to parental smoking and the risk of type 2 diabetes: Are lifestyle‐related factors more important?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2015)

Glycated hemoglobin variability and retinopathy progression in type 1 diabetes: Is month‐to‐moth instability a better predictor?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Commentary on risk factors for first and subsequent cardiovascular disease events in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study
por: Lin, Chun‐Hsien, et al.
Publicado: (2020)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Diabetes, Glycemic Control, and Risk of Infection Morbidity and Mortality: A Cohort Study
por: Chang, Chia-Hsuin, et al.
Publicado: (2019)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
por: Hilgenfeld, Rolf, et al.
Publicado: (2014)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes
por: Habel, Laurel A., et al.
Publicado: (2013)

Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan
por: Liu, Chia-Hung, et al.
Publicado: (2013)

Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?: A French nationwide cohort study based on national administrative databases
por: Fagot, Jean-Paul, et al.
Publicado: (2013)

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
por: Tang, Xulei, et al.
Publicado: (2012)

MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study
por: Chuang, Ya-Wen, et al.
Publicado: (2015)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Privacy-protecting estimation of adjusted risk ratios using modified Poisson regression in multi-center studies
por: Shu, Di, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q2c90u22rhag6gr2eno250qqb0